艾美疫苗(06660.HK) 公布,其自主研发的13价结合肺炎疫苗于昨日(10月31日)向国家药监局提交药品上市注册。
根据已完成揭盲的III期临床研究结果显示,集团的13价结合肺炎疫苗具有良好的免疫原性和安全性,达到临床预设目标。此外,集团全资子公司艾美坚持生物制药已取得生产该产品相应的药品生产许可证。
集团指出,据权威机构测算,全球13价结合肺炎疫苗缺口高达1.8亿剂,但目前全球仅三家企业获批供应,集团该产品上市之后,将成为重要供应商,并大幅提升业绩。(jl/w)(港股报价延迟最少十五分钟。沽空资料截至 2024-10-31 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.